Further mechanistic studies of LAL in CAD will shed light on the benefits and risks in therapeutically targeting LAL, particularly in the context of LAL ERT that is currently approved for use in patients with LAL deficiency. This evidence concerns the gene LIPA and coronary artery disorder.